Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 34/75 ]
NASDAQ | Common Stock
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.
It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.
The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers.
SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 23, 26 | -0.04 Increased by +63.64% | -0.12 Increased by +67.82% |
| Nov 10, 25 | -0.11 Increased by +31.25% | -0.17 Increased by +35.29% |
| Aug 5, 25 | -0.14 Increased by +36.36% | -0.18 Increased by +22.22% |
| May 5, 25 | -0.15 Increased by +44.44% | -0.22 Increased by +31.03% |
| Feb 24, 25 | -0.11 Increased by +59.26% | -0.13 Increased by +18.09% |
| Nov 12, 24 | -0.16 Increased by +36.00% | -0.24 Increased by +33.33% |
| Aug 5, 24 | -0.22 Increased by +26.67% | -0.28 Increased by +21.43% |
| May 6, 24 | -0.27 Increased by +15.62% | -0.31 Increased by +12.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 56.35 M Increased by +15.00% | -1.65 M Increased by +63.34% | Decreased by -2.92% Increased by +68.12% |
| Sep 30, 25 | 48.66 M Increased by +20.61% | -4.57 M Increased by +30.56% | Decreased by -9.38% Increased by +42.42% |
| Jun 30, 25 | 48.63 M Increased by +21.67% | -6.15 M Increased by +31.18% | Decreased by -12.65% Increased by +43.44% |
| Mar 31, 25 | 47.29 M Increased by +24.88% | -6.54 M Increased by +40.00% | Decreased by -13.83% Increased by +51.96% |
| Dec 31, 24 | 49.00 M Increased by +26.10% | -4.50 M Increased by +59.07% | Decreased by -9.17% Increased by +67.54% |
| Sep 30, 24 | 40.34 M Increased by +18.60% | -6.58 M Increased by +34.39% | Decreased by -16.30% Increased by +44.68% |
| Jun 30, 24 | 39.97 M Increased by +20.01% | -8.94 M Increased by +20.23% | Decreased by -22.36% Increased by +33.53% |
| Mar 31, 24 | 37.87 M Increased by +15.77% | -10.90 M Increased by +1.99% | Decreased by -28.80% Increased by +15.34% |